| US 7,544,691 B2 | ||
| Guanidine derivatives | ||
| Volker Breu, Schliengen (Germany); Anja Fecher, Weil am Rhein (Germany); Heinz Fretz, Riehen (Switzerland); Thomas Giller, Wintersingen (Switzerland); Kurt Hilpert, Hofstetten (Switzerland); and Olivier Valdenaire, Allschwil (France) | ||
| Assigned to Actelion Pharmaceuticals, Ltd., Allschwil (Switzerland) | ||
| Appl. No. 10/570,517 PCT Filed Sep. 03, 2004, PCT No. PCT/CH2004/000556 § 371(c)(1), (2), (4) Date Nov. 02, 2006, PCT Pub. No. WO2005/023781, PCT Pub. Date Mar. 17, 2005. |
||
| Prior Publication US 2007/0123510 A1, May 31, 2007 | ||
| Int. Cl. A61K 31/517 (2006.01) | ||
| U.S. Cl. 514—266.4 [544/292] | 9 Claims |
1. A compound of formula
 A represents N;
B represents a C atom substituted with R1;
R1 represents hydrogen or a lower alkyl, haloalkyl, alkylamino, cycloalkylamino, alkoxy, haloalkoxy or alkylthio group;
Q together with the pyrimidine ring forms a 6,7-dihydro-5H-cyclopentapyrimidine, 5,6,7,8-tetrahydro-quinazoline, 6,7,8,9-tetrahydro-5H-cycloheptapyrimidine
or 5,6,7,8,9,10-hexahydrocyclooctapyrimidine skeleton;
R2 means methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert.-butyl, 1,1-dimethylpropyl or phenyl;
R3-R7 mean hydrogen, alkyl, alkenyl, aryl, or cyanoalkyl;
or a pharmaceutically acceptable acid addition salt of such a compound.
|